Neurologic Imaging

Which MRI Is Best for Surveillance in a Stable Adult with Demyelinating Disease?

·
Which MRI Is Best for Surveillance in a Stable Adult with Demyelinating Disease?

A 42-year-old patient with a known diagnosis of multiple sclerosis arrives for a routine annual follow-up. They have been on the same disease-modifying therapy for two years and report no new or worsening neurologic symptoms. Their clinical examination is stable and unchanged from the previous year’s visit. You are now considering whether to order surveillance imaging to assess for subclinical disease activity, a standard practice to ensure their treatment remains effective. The central question is not if to image, but what to order to get the most relevant information without unnecessary procedures. For this specific scenario, the American College of Radiology (ACR) Appropriateness Criteria rate several MRI studies as Usually Appropriate, with a comprehensive evaluation often including MRI of the brain as well as the cervical and thoracic spine.

Who Fits This Clinical Scenario for Surveillance Imaging?

This guidance applies specifically to adult patients with an established, confirmed diagnosis of a central nervous system (CNS) demyelinating disease, most commonly multiple sclerosis (MS). The crucial qualifier for this workflow is that the patient is clinically stable. This means they have no new, worsening, or fluctuating neurologic deficits on history or physical examination. The imaging is being ordered for the express purpose of surveillance—to monitor for asymptomatic disease progression or to establish a new baseline after a change in therapy.

This workflow should not be applied to patients who present differently, even if they have a known demyelinating disease. Key exclusion criteria include:

  • New or Progressive Deficits: If a patient with known MS presents with new symptoms like optic neuritis, weakness, or sensory changes, they fit a different clinical scenario requiring an urgent diagnostic workup, not routine surveillance.
  • Initial Diagnostic Uncertainty: This guidance is not for a patient presenting with initial symptoms concerning for a demyelinating disease. That workup follows a separate pathway to establish a diagnosis.
  • Suspected Transverse Myelitis: A patient presenting with acute sensorimotor symptoms localized below a specific spinal cord level requires an urgent evaluation for transverse myelitis, a distinct ACR scenario.

Correctly identifying the patient as stable and the imaging intent as surveillance is essential for applying this guidance appropriately.

What Are You Monitoring For with Surveillance Imaging?

In a stable patient, surveillance imaging is not about diagnosing a new condition but about quantifying the activity of a known one. The “differential” in this context refers to the potential findings that can alter management, even in the absence of clinical symptoms. The primary goal is to detect evidence of ongoing disease that the neurologic exam might miss.

Subclinical Disease Activity
This is the most critical finding to identify. Surveillance MRI can reveal new or enlarging T2-hyperintense or Fluid-Attenuated Inversion Recovery (FLAIR) lesions in the brain or spinal cord that have not produced any noticeable symptoms. The appearance of such lesions indicates that the current disease-modifying therapy (DMT) may not be fully controlling the inflammatory process, a finding that often prompts a discussion about escalating treatment.

New Gadolinium-Enhancing Lesions
The presence of contrast enhancement signifies active inflammation with blood-brain barrier breakdown. Identifying a new enhancing lesion on a surveillance scan is a powerful indicator of recent, focal disease activity. This finding provides objective evidence of breakthrough disease and carries significant weight in decisions to switch or modify the patient’s therapeutic regimen.

Progressive Lesion Burden and Atrophy
Beyond individual new lesions, surveillance imaging allows for the longitudinal assessment of total T2 lesion burden and brain volume. A gradual increase in lesion volume or an accelerated rate of brain or spinal cord atrophy are markers of insidious neurodegenerative progression. Tracking these changes over time helps build a comprehensive picture of the disease trajectory.

Treatment-Related Complications
While less common, surveillance scans play a role in monitoring for potential adverse effects of certain DMTs. For example, they can help in the early detection of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with some immunomodulatory therapies.

Why Is MRI of the Spine and Brain the Recommended Study for Surveillance?

The ACR designates several MRI protocols as Usually Appropriate for this scenario, reflecting the need to monitor both the brain and spinal cord. While brain MRI is the most common surveillance tool, a complete assessment often includes the spinal cord. For this reason, MRI cervical and thoracic spine without and with IV contrast and MRI head without and with IV contrast are both rated as Usually Appropriate. These studies provide the highest sensitivity for detecting the subtle signs of subclinical disease activity central to this workup.

MRI excels at visualizing demyelinating plaques due to its superior soft-tissue contrast. T2-weighted and FLAIR sequences are highly sensitive for identifying both old and new lesions. The addition of gadolinium-based IV contrast is crucial for determining lesion activity; enhancement indicates active inflammation. Performing scans both without and with contrast allows for the direct comparison needed to confidently identify new enhancing lesions against the background of pre-existing, non-enhancing ones. There is no ionizing radiation (0 mSv) associated with MRI, making it ideal for the repeated imaging required for long-term disease surveillance.

In contrast, other imaging modalities are rated lower for this specific purpose:

  • CT head without and with IV contrast is rated Usually not appropriate. CT has poor sensitivity for detecting demyelinating plaques, especially non-enhancing or chronic lesions. It also exposes the patient to ionizing radiation (☢☢☢ 1-10 mSv), which is undesirable for routine surveillance in a chronic condition.
  • MRI lumbar spine without and with IV contrast is also rated Usually not appropriate. While demyelinating lesions can occur in the lumbar spine, they are far less common than in the cervical and thoracic regions. For routine surveillance in an asymptomatic patient, imaging the lumbar spine is generally low-yield and not recommended unless specific symptoms point to that area.

The decision to use contrast, or to image the brain, spine, or both, depends on institutional protocols and the patient’s specific disease history. However, the principle remains: high-resolution MRI is the standard of care. Once you’ve decided on the appropriate study, our protocol guide can help with technical specifics. For details on the non-contrast portion of the spinal exam, see our guide: MRI Cervical Spine Without Contrast.

What’s Next After MRI? Downstream Workflow

The results of surveillance imaging directly influence the patient’s long-term management plan. The downstream workflow depends entirely on whether the scan shows disease stability or progression.

  • If the study is stable (no new or enhancing lesions): This result provides reassurance that the current DMT is effective. The typical next step is to continue the current treatment plan and schedule the next clinical and imaging follow-up, often in 12-24 months, depending on the specific therapy and clinical context.
  • If the study shows new T2/FLAIR lesions but no enhancement: This indicates subclinical disease activity has occurred since the last scan. While not an emergency, it is a significant finding that warrants a discussion with the patient about the risks and benefits of switching to a different or more potent DMT to achieve better disease control.
  • If the study shows new contrast-enhancing lesions: This is clear evidence of active, ongoing inflammation. This finding often serves as a primary trigger for changing therapy. The discussion with the patient will focus on escalating to a more effective DMT to prevent further inflammatory attacks and subsequent disability accumulation.
  • If the study is negative but the patient develops new symptoms: If a patient’s clinical status changes between scheduled scans, the surveillance plan is abandoned in favor of a diagnostic workup. This would shift them into the “Known demyelinating disease, new or progressive neurologic deficits” scenario, requiring prompt imaging to evaluate the new symptoms.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can undermine the value of surveillance imaging in this stable patient population. First, inconsistent imaging protocols or scanners between time points can create artifactual changes that mimic or obscure true disease progression. It is crucial to obtain follow-up scans at the same institution using a standardized MS protocol. Second, omitting gadolinium contrast without a clear contraindication prevents the assessment of active inflammation, which is a primary goal of the scan. Third, failing to directly compare the new scan with the most recent prior study can lead to missing subtle new lesions or misinterpreting old ones as new. Finally, over-interpreting non-specific white matter changes as demyelinating lesions can lead to unnecessary anxiety and treatment changes. If the findings are equivocal or complex, consultation with a neuroradiologist or a neurologist specializing in MS is the appropriate next step.

Related ACR Topics and Tools

Navigating imaging choices for demyelinating diseases requires familiarity with multiple clinical scenarios and imaging techniques. For a comprehensive overview of all variants, from initial diagnosis to acute relapse, please consult our parent topic hub article. For tools to assist with ordering and patient communication, see the resources below.

Frequently Asked Questions

How often should surveillance MRI be performed in a stable patient with MS?

The optimal frequency is debated and depends on the specific disease-modifying therapy (DMT), disease history, and time from diagnosis. A common approach is to obtain a baseline brain MRI 3-6 months after starting a new DMT, followed by annual scans for the first few years. If the patient remains stable on imaging and clinically, the interval may be extended to every 2-3 years.

Is it necessary to image both the brain and the full spine for every surveillance scan?

Not always. While the ACR rates both brain and spine MRI as ‘Usually Appropriate,’ many centers prioritize brain MRI for routine annual surveillance unless the patient has a history of significant spinal cord disease or develops new spinal symptoms. Spinal cord imaging is often performed at baseline and then repeated less frequently than brain imaging or if there is a clinical change.

Should I order a surveillance MRI if my stable patient has a contraindication to gadolinium contrast?

Yes. An MRI without IV contrast is still rated as ‘Usually Appropriate.’ While you will lose the ability to detect active enhancement, the scan can still identify new or enlarging T2/FLAIR lesions, which is valuable information for assessing subclinical disease activity. The absence of contrast should be clearly communicated to the radiologist.

What if my patient is clinically stable but reports vague, non-specific symptoms like fatigue?

Fatigue is a common and complex symptom in MS that does not typically correlate with new lesions on MRI. If the neurologic examination is stable and there are no new objective deficits, the patient still fits this surveillance scenario. The presence of fatigue alone does not automatically shift the patient into an ‘acute relapse’ category requiring urgent diagnostic imaging.

Does this surveillance guidance apply to other demyelinating diseases besides MS?

While MS is the most common indication, the principles can apply to other CNS inflammatory demyelinating conditions like neuromyelitis optica spectrum disorder (NMOSD) or MOG-associated disease (MOGAD). However, imaging protocols and the significance of findings can differ. For instance, in NMOSD, surveillance of the spinal cord and optic nerves is often prioritized. Consultation with a specialist is recommended for these less common conditions.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026